Antimicrobial strategy for targeted elimination of different microbes, including bacterial, fungal and viral pathogens.
Journal
Communications biology
ISSN: 2399-3642
Titre abrégé: Commun Biol
Pays: England
ID NLM: 101719179
Informations de publication
Date de publication:
04 07 2022
04 07 2022
Historique:
received:
13
07
2021
accepted:
14
06
2022
entrez:
5
7
2022
pubmed:
6
7
2022
medline:
7
7
2022
Statut:
epublish
Résumé
The continuous emergence of microbial pathogens for which there are no effective antimicrobials threatens global health, necessitating novel antimicrobial approaches. Here, we present a targeted antimicrobial strategy that can be applied to various microbial pathogens. A photoimmuno-conjugate composed of an antibody against the target pathogen and a photoplastic phthalocyanine-derivative probe that generates photo-induced mechanical stress was developed based on photoimmuno-technology. This strategy, named as photoimmuno-antimicrobial strategy (PIAS), eliminates targeted pathogens, regardless of the target species or drug-resistance status. Specifically, PIAS acts on a broad range of microbes, including the bacterial pathogen Staphylococcus aureus, fungal pathogen Candida albicans, including their drug-resistant strains, and viral pathogen SARS-CoV-2, the causative agent of COVID-19. Furthermore, PIAS protects mice from fatal infections without damaging the non-targeted host microbiota and tissues. This study may contribute to the development of next-generation anti-infective therapies.
Identifiants
pubmed: 35788695
doi: 10.1038/s42003-022-03586-4
pii: 10.1038/s42003-022-03586-4
pmc: PMC9253063
doi:
Substances chimiques
Anti-Bacterial Agents
0
Anti-Infective Agents
0
Banques de données
figshare
['10.6084/m9.figshare.19776094']
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
647Informations de copyright
© 2022. The Author(s).
Références
Photochem Photobiol. 2006 Nov-Dec;82(6):1634-7
pubmed: 16898858
Methods Mol Biol. 2008;431:241-54
pubmed: 18287761
N Engl J Med. 1996 May 2;334(18):1178-84
pubmed: 8602186
Jpn J Infect Dis. 2020 Jul 22;73(4):304-307
pubmed: 32074516
Proc Natl Acad Sci U S A. 2020 Mar 31;117(13):7001-7003
pubmed: 32165541
Nat Rev Microbiol. 2009 Sep;7(9):629-41
pubmed: 19680247
FEBS Lett. 1979 Sep 15;105(2):195-6
pubmed: 488348
Nature. 2010 May 20;465(7296):346-9
pubmed: 20485435
Immunol Rev. 2017 Sep;279(1):90-105
pubmed: 28856737
Clin Microbiol Rev. 1997 Jul;10(3):505-20
pubmed: 9227864
J Vis Exp. 2014 Sep 06;(91):e51728
pubmed: 25225958
Nat Rev Cancer. 2003 May;3(5):380-7
pubmed: 12724736
Nature. 2019 Jan;565(7741):600-605
pubmed: 30675064
Nat Rev Drug Discov. 2002 Nov;1(11):895-910
pubmed: 12415249
Bioconjug Chem. 2012 Mar 21;23(3):604-9
pubmed: 22369484
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Lancet. 2022 Feb 12;399(10325):629-655
pubmed: 35065702
Nat Med. 2004 Dec;10(12 Suppl):S122-9
pubmed: 15577930
Science. 2016 Dec 16;354(6318):
pubmed: 27980159
Oncotarget. 2016 Mar 22;7(12):14143-52
pubmed: 26909859
Nat Rev Drug Discov. 2010 Sep;9(9):719-27
pubmed: 20725094
Nat Med. 2011 Nov 06;17(12):1685-91
pubmed: 22057348
Lancet. 2017 Jun 17;389(10087):2415-2429
pubmed: 27939064
PLoS One. 2011 Mar 24;6(3):e18246
pubmed: 21455319
Sci Rep. 2018 Apr 3;8(1):5480
pubmed: 29615776
ACS Cent Sci. 2018 Nov 28;4(11):1559-1569
pubmed: 30555909
Lancet. 2016 Jan 9;387(10014):168-75
pubmed: 26603918
J Bacteriol. 1948 Feb;55(2):257-76
pubmed: 16561455
Science. 2008 Mar 7;319(5868):1391-4
pubmed: 18276850